Himalaya Nutravedics India Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Himalaya Nutravedics India Limited's successfully completed its Initial Public Offering and commenced trading on Sep 29, 2026 at the BSE exchange. The company raised 24,99,600 Shares through this public offering, comprising 24,99,600 Shares in fresh capital.
The IPO was priced within the band of ₹100 to ₹106, with minimum application lots of 1200 shares. The offering attracted significant investor interest during its subscription period from Sep 22, 2026 to Sep 24, 2026.
Share allotment was finalized on Sep 25, 2026, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India, along with offering third-party contract manufacturing services for other companies in this space. The company has a diversified product portfolio comprising classical Ayurvedic formulations based on traditional texts, proprietary Ayurvedic products, and nutraceutical supplements, available in various dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils. It operates on a hybrid business model that balances its own branded products with contract manufacturing, supported by an integrated in-house manufacturing facility located in Hyderabad, Telangana. As of September 2025, its products are distributed across multiple states including Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh, with offerings catering to a wide range of wellness segments such as digestive health, immunity, metabolic health, joint care, reproductive health, respiratory wellness, pain management, and overall well-being, aligned with regulatory standards.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Integrated Multi-Dosage Manufacturing: The company can manufacture different dosage forms, including capsules, tablets, oils, liquid orals and powders. This enables it to serve varied product needs across multiple therapeutic categories.
- Strong Doctor Acceptance: The company promotes its branded products through healthcare practitioners, with product acceptance driven by performance rather than mass advertising. This supports its established branded product portfolio.
- Long-Standing Relationships: Himalaya Nutravedics has built lasting relationships with its suppliers and customers. These relationships help support smooth procurement and sales operations.
- Dependence on Ayurvedic Products: Ayurvedic products contributed 94.57%, 92.09% and 79.27% of revenue from operations in Fiscal 2026, 2025 and 2024, respectively. A decline in demand for these products could negatively affect the company’s business and financial performance.
- Customer Concentration: The top 10 customers contributed 81.24%, 86.97% and 84.19% of revenue from operations in Fiscal 2026, 2025 and 2024, respectively. Losing key customers or facing lower or delayed orders could impact revenue, financial condition and cash flows.
- Supplier Concentration: The company has historically sourced a significant share of its requirements from its top 10 suppliers. Any disruption in these supplier relationships could affect the availability of raw materials and other essential supplies.
- Rohit Asawa
- Divya Asawa
- Chanda Asawa
- Rama Raju
Himalaya Nutravedics India Limited
Kfin Technologies Limited